

July 10, 2025

**Notification Regarding Acquisition of Treasury Stock and Repurchase of Treasury Shares through Off-Auction Own Share Repurchase Trading System(ToSTNeT-3)**

(Acquisition of the company's own shares b under the regulations of the Articles of Incorporation pursuant to Article 165, paragraph (2) of the Companies Act, and repurchase of treasury shares through ToSTNeT-3)

Hisamitsu Pharmaceutical Co., Inc. (Head Office: Tosu City, Saga Prefecture; President and CEO: NAKATOMI, Kazuhide) is pleased to announce that it has resolved matters relating to the acquisition of its own shares pursuant to Article 156 of the Companies Act of Japan (the Companies Act) as applied under Article 165, paragraph (3) of the Companies Act, and has also determined the specific method for the acquisition at the meeting of the board of directors held today. The details are as follows:

**1. Reason for acquiring the company's own shares**

To enhance sustainable value for the company and its shareholders, we have formulated a Basic Policy on Cash Allocation\*. We aim to implement shareholder returns exceeding 50 billion yen (including dividends and share buybacks) over a five-year period, from the fiscal year ending February 2027 to the fiscal year ending February 2031. Under this policy, Hisamitsu Pharmaceutical will acquire treasury shares to strengthen shareholder returns, considering its recent performance, cash inflow forecasts, and stock market conditions.

**2. Method of acquisition**

At 8:45 a.m. on July 10, 2025, a consigned purchase order will be placed with the Tokyo Stock Exchange Off-Auction Own Share Repurchase Trading System (ToSTNeT-3) at the closing price of ¥4,027 for today, July 11, 2025 (no changes to other transaction systems or transaction times will be made). The purchase order will apply only to the specified transaction time.

**3. Details of matters concerning the acquisition**

- |  |  |
|--|--|
| (1) Type of shares to be acquired          | Common share of Hisamitsu Pharmaceutical   |
| (2) Total number of shares to be acquired  | 2 million shares (Maximum)<br>2.72% of total number of outstanding shares<br>[excluding treasury shares] |
| (3) Total amount of acquisition cost       | 8,054 million yen (Maximum)  |
| (4) Announcement of results of acquisition | The acquisition results will be announced after the close of trading at 8:45 A.M. on July 11, 2025       |

Note 1: No change will be made to the number of shares specified above. Note, however, that part or all of the acquisition may not be carried out depending on market trends and other factors.

Note 2: The purchase will be made on the basis of sell orders corresponding to the number of shares scheduled to be acquired.

Furthermore, the Company plans to conduct a market purchase on the Tokyo Stock Exchange, with the maximum number and amount of shares to be acquired being the difference between the total number and amount of shares resolved at the Board of Directors meeting held today and the total number and amount of shares acquired as stated in item 3 above.

(Reference) Details of Resolution of the board of directors meeting held on July 10, 2025

- |   |  |
|---|--|
| (1) Type of shares to be acquired         | Common share of Hisamitsu Pharmaceutical   |
| (2) Total number of shares to be acquired | 3 million shares (Maximum)<br>4.09% of total number of outstanding shares [excluding treasury shares]  |
| (3) Total amount of acquisition cost      | 15 billion yen (Maximum)   |
| (4) Period for acquisition                | From July 11, 2025, to December 31, 2025   |
| (5) Method of acquisition                 | (i) Acquire through an off-auction own share repurchase transaction (ToSTNeT-3)<br>(ii) Acquire in the open market through discretionary trading on the Tokyo Stock Exchange |

\*Regarding Basic Policy on Cash Allocation

[https://global.hisamitsu/pdf/news\\_release\\_E\\_250310.pdf](https://global.hisamitsu/pdf/news_release_E_250310.pdf)

